An interventional study of ICG fluorescence imaging technology and Imaging Photoplethysmography System in Anastomosis, Perfusion and Postoperative Complications, sponsored by Saint Petersburg State University, Russia. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Saint Petersburg State University, Russia · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled trial compares a novel optical technique against the standard of care for assessing tissue perfusion in gastrointestinal surgery. Participants are randomized to receive either intraoperative imaging photoplethysmography (iPPG) or indocyanine green (ICG) fluorescence imaging. In the ICG group, the fluorescence data are comprehensively analyzed in two distinct ways: (1) Qualitative Assessment: real-time visual interpretation of the angiogram flow by the operating surgeon; and (2) Quantitative Assessment: software-based analysis of fluorescence kinetics (e.g., time-to-peak, maximum intensity) to generate objective perfusion parameters. The study aims to determine the agreement between the iPPG-based evaluations and both the qualitative and quantitative dimensions of the ICG standard.
This randomized, parallel-group clinical study aims to compare two intraoperative imaging strategies for assessing tissue perfusion in a spectrum of gastrointestinal anastomoses, including both gastro-intestinal and entero-enteric reconstructions. The primary objective is to evaluate the diagnostic performance and clinical utility of a novel, non-contact optical technique-imaging photoplethysmography (iPPG)-against the current clinical standard, indocyanine green (ICG) fluorescence imaging.
Eligible and consented patients will be randomly assigned to one of two arms. The iPPG Arm will undergo perfusion evaluation solely using the investigational iPPG system. This method leverages a conventional video camera to detect pulsatile blood volume changes in microvascular tissue, offering a non-invasive, contrast-agent-free approach to perfusion assessment. The ICG Arm will be assessed using the standard fluorescence imaging protocol. A key feature of the study design is the pre-specified, comprehensive analysis within the ICG arm, which will incorporate both a qualitative assessment (the surgeon's real-time visual interpretation of the angiogram) and a quantitative analysis (computer-based calculation of fluorescence kinetics parameters, such as time-to-peak and inflow slope).
The study is designed to provide a head-to-head comparison of the two guiding strategies. Outcomes from the iPPG-guided arm will be systematically benchmarked against those from the ICG-guided arm. Furthermore, the internal comparison between qualitative and quantitative assessments within the ICG arm will yield valuable insights into the optimal methodology for interpreting perfusion data in clinical practice. This design allows for the evaluation of iPPG not only as a potential alternative to ICG but also for the refinement of the standard itself.
1,343 studies on the registry are indexed under Postoperative Complications; 314 are open to participants now.
This study's planned enrollment of 200 is above the median of 113 across 773 interventional studies indexed under Postoperative Complications.
Browse Postoperative Complications studies →Saint Petersburg State University, Russia is the lead sponsor of 34 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm undergo intraoperative tissue perfusion assessment guided by the standard Indocyanine Green (ICG) fluorescence imaging. This involves intravenous ICG injection. Perfusion is evaluated comprehensively through both qualitative (surgeon's visual interpretation) and quantitative (computer-based analysis of fluorescence kinetics, e.g., time-to-peak) methods. This arm represents the current standard of care.
Drug: ICG fluorescence imaging technology · Device: Imaging Photoplethysmography System
Participants in this arm undergo intraoperative tissue perfusion assessment guided by the investigational Imaging Photoplethysmography (iPPG) system. This non-contact, camera-based technique detects microvascular blood volume changes without requiring exogenous contrast agents. The surgical team uses the real-time iPPG perfusion maps to evaluate anastomotic viability and guide surgical decisions.
Drug: ICG fluorescence imaging technology · Device: Imaging Photoplethysmography System
This intervention involves the intravenous injection of the fluorescent contrast agent Indocyanine Green (ICG), followed by imaging with a near-infrared fluorescence camera system. Upon illumination with near-infrared light, ICG in the bloodstream fluoresces, allowing for real-time visualization of blood flow and tissue perfusion (qualitative assessment). Additionally, the fluorescence intensity over time can be recorded for subsequent quantitative analysis of perfusion kinetics.
Also known as: ICG Imaging, ICG Angiography, Near-Infrared Fluorescence Imaging
Imaging photoplethysmography is a non-contact, camera-based optical imaging technique. This investigational system operates by detecting subtle modulations in optical signals associated with pulsatile blood volume changes in microvascular tissue. It utilizes a conventional video camera to capture these signals and generates real-time tissue perfusion maps without the need for any exogenous contrast agents. The system is designed to provide intraoperative guidance for assessing tissue viability during gastrointestinal anastomoses.
Also known as: iPPG, PPG Imaging
Incidence of Anastomotic Leak
Comparison of the rate of clinically significant anastomotic leak between the iPPG-guided group and the ICG-guided group. Anastomotic leak is defined as a full-thickness defect requiring radiological, endoscopic, or surgical intervention, as confirmed by an independent clinical events committee within 30 days postoperatively.
Time frame: 30 days postoperatively
Incidence of Anastomotic Leak: Qualitative vs Quantitative ICG Assessment
Comparison of the rate of clinically significant anastomotic leak between patients whose intraoperative assessment was based on qualitative ICG imaging (surgeon's visual interpretation) versus those assessed with quantitative ICG parameters (software-based kinetic analysis). Anastomotic leak is defined as a full-thickness gastrointestinal defect requiring postoperative radiological, endoscopic, or surgical intervention, as confirmed by an independent adjudication committee. This analysis will be performed specifically within the cohort of patients randomized to the ICG arm.
Time frame: 30 days postoperatively
Diagnostic Performance for Predicting Anastomotic Leak
To evaluate and compare the diagnostic accuracy of the intraoperative iPPG assessment versus the standard ICG assessment (including both qualitative and quantitative methods) in predicting the occurrence of a postoperative anastomotic leak. The perfusion assessment during surgery will be dichotomized as 'inadequate' or 'adequate'. Diagnostic performance metrics including Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), and the Area Under the Receiver Operating Characteristic Curve (AUC-ROC) will be calculated for each modality against the clinical outcome of anastomotic leak.
Time frame: he perfusion assessment is performed intraoperatively. The outcome (anastomotic leak) is assessed at 30 days postoperatively.
Rate of Anastomotic Revision Based on Perfusion Assessment
To quantify and compare the immediate impact of perfusion assessment on surgical decision-making by recording the frequency at which the operating surgeon decides to revise the anastomosis (i.e., resect and re-anastomose the bowel segment) based solely on the intraoperative findings of either iPPG or ICG imaging. The revision rate will be calculated as the proportion of patients in each arm (iPPG and ICG) for whom the anastomosis was revised due to perceived inadequate perfusion.
Time frame: Intraoperative (Measured immediately following the perfusion assessment of the initially constructed anastomosis)
Overall Postoperative Complication Rate
To comprehensively evaluate and compare the overall postoperative morbidity between the iPPG-guided group and the ICG-guided group. All complications occurring within 30 days after surgery will be recorded and graded according to the Clavien-Dindo classification system. This standardized system categorizes complications based on the level of intervention required for management, ranging from Grade I (any deviation from the normal postoperative course not requiring pharmacological/surgical intervention) to Grade V (death). The comparison will focus on the incidence of complications of Grade II and above.
Time frame: 30 days postoperatively
Rate of Re-intervention
To compare the incidence of unplanned, procedure-related re-interventions between the iPPG-guided and ICG-guided groups. A re-intervention is defined as any subsequent surgical, endoscopic, or radiology-guided invasive procedure required to manage a complication related to the initial gastrointestinal resection and anastomosis (e.g., control of bleeding, drainage of an intra-abdominal collection, or repair of an anastomotic leak). Planned, staged procedures are excluded. The rate is calculated as the proportion of patients in each group undergoing at least one such re-intervention.
Time frame: 30 days postoperatively
Surgeon Confidence Score
To quantify the surgeon's confidence in the adequacy of the anastomotic perfusion following the intraoperative assessment. Immediately after evaluating the perfusion with the assigned modality (iPPG or ICG) and before abdominal closure, the primary surgeon will rate their confidence on an 11-point numerical rating scale, ranging from 0 (no confidence in anastomotic viability) to 10 (absolute confidence in anastomotic viability). The mean confidence scores will be compared between the two study arms.
Time frame: Intraoperative (Assessed immediately after perfusion evaluation and before fascial closure)
Time from Imaging to Decision
To compare the workflow efficiency between the iPPG and ICG assessment modalities. This measure records the time elapsed from the moment a clear, interpretable perfusion image is first available on the display to the moment the surgeon verbally communicates the final decision regarding the anastomosis (e.g., "proceed as is," "revise anastomosis," "create stoma"). The time is recorded in seconds for each assessed anastomosis.
Time frame: Intraoperative (Measured for each anastomosis assessment event)
Not enrolling at this site.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Apr 2026, 29 months after the start.
Of 395 non-industry interventional studies with no phase under Postoperative Complications, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 29 months is above that.
Counting every sponsor, half of 399 studies reached it within 20 months; a quarter within 8 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saint Petersburg State University, Russia